Article
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
The lancet. Gastroenterology & hepatology - 1 Sept 2018
Domingo Enric, Camps Carme, Kaisaki Pamela J, Parsons Marie J, Mouradov Dmitri, Pentony Melissa M, Makino Seiko, Palmieri Michelle, Ward Robyn L, Hawkins Nicholas J, Gibbs Peter, Askautrud Hanne, Oukrif Dahmane, Wang Haitao, Wood Joe, Tomlinson Evie, Bark Yasmine, Kaur Kulvinder, Johnstone Elaine C, Palles Claire, Church David N, Novelli Marco, Danielsen Havard E, Sherlock Jon, Kerr David, Kerr Rachel, Sieber Oliver, Taylor Jenny C, Tomlinson Ian
Abstract excerpt
BACKGROUND: Molecular indicators of colorectal cancer prognosis have been assessed in several studies, but most analyses have been restricted to a handful of markers. We aimed to identify prognostic biomarkers for colorectal cancer by sequencing panels of multiple driver genes. METHODS: In stage II or III colorectal cancers from the QUASAR 2 open-label randomised phase 3 clinical trial and an Australian...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.